Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own3.70% Shs Outstand104.59M Perf Week10.15%
Market Cap760.37M Forward P/E- EPS next Y-1.12 Insider Trans19.52% Shs Float91.63M Perf Month5.36%
Income-118.40M PEG- EPS next Q-0.28 Inst Own54.00% Short Float18.69% Perf Quarter-4.84%
Sales55.50M P/S13.70 EPS this Y-3.10% Inst Trans4.88% Short Ratio11.56 Perf Half Y28.90%
Book/sh-0.74 P/B- EPS next Y-13.10% ROA-66.60% Target Price13.67 Perf Year83.12%
Cash/sh0.89 P/C8.19 EPS next 5Y5.60% ROE233.40% 52W Range2.05 - 8.25 Perf YTD36.40%
Dividend- P/FCF- EPS past 5Y-20.00% ROI-176.90% 52W High-11.88% Beta-
Dividend %- Quick Ratio1.10 Sales past 5Y160.30% Gross Margin- 52W Low254.63% ATR0.33
Employees254 Current Ratio1.10 Sales Q/Q50.30% Oper. Margin- RSI (14)60.75 Volatility4.34% 5.09%
OptionableYes Debt/Eq- EPS Q/Q45.20% Profit Margin- Rel Volume0.94 Prev Close7.31
ShortableYes LT Debt/Eq- EarningsAug 11 BMO Payout- Avg Volume1.48M Price7.27
Recom1.60 SMA205.57% SMA5010.57% SMA20022.31% Volume1,391,481 Change-0.55%
08-Jul-14Resumed Brean Capital Buy $16
20-Jun-14Reiterated Oppenheimer Outperform $10 → $8.50
09-Aug-13Reiterated Oppenheimer Outperform $12 → $10
25-Jun-13Initiated Mizuho Buy $12
08-May-12Initiated Oppenheimer Outperform $12
12-Sep-14 08:59AM  5 Stocks Under $10 Soaring Higher at TheStreet
10-Sep-14 06:41AM  Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? Zacks
09-Sep-14 06:42AM  Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? Zacks
08-Sep-14 02:25PM  3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, Merrimack & Amicus Benzinga
28-Aug-14 06:58AM  Is Merrimack Pharmaceuticals (MACK) Stock a Solid Choice Right Now? Zacks
19-Aug-14 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials EDGAR Online Financials
11-Aug-14 07:18AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
07:07AM  Q2 2014 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
07:05AM  Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval GlobeNewswire
07:00AM  Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results GlobeNewswire
07-Aug-14 08:20AM  4 Biotech Stocks Where Analysts See 100% Upside, or Even Higher at 24/7 Wall St. +5.03%
04-Aug-14 04:01PM  Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call GlobeNewswire
08-Jul-14 11:17AM  Is Now The Time To Buy Merrimack Pharmaceuticals? at Seeking Alpha
03-Jul-14 10:36AM  4 Biotech Stocks Worth A Look Ahead Of FDA Approvals Benzinga
30-Jun-14 11:37AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online
28-Jun-14 09:21AM  Key Stocks With Insider Buying This Week at 24/7 Wall St.
25-Jun-14 04:05PM  Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer GlobeNewswire
04:05PM  Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
12:53PM  5 Stocks With Big Insider Buying at TheStreet
12:53PM  5 Stocks With Big Insider Buying
24-Jun-14 08:04PM  Why Micron Technology, Qihoo 360, and Merrimack Pharmaceuticals Rose Today at Motley Fool +5.76%
08:04PM  Why Micron Technology, Qihoo 360, and Merrimack Pharmaceuticals Rose Today
23-Jun-14 03:45PM  Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights Zacks
03:45PM  Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights
02:55PM  Nasdaq stocks posting largest percentage decreases
07:45AM  Merrimack Pharmaceuticals (MACK) Crumbles: Stock Tanks by 11.3% Zacks
07:45AM  Merrimack Pharmaceuticals (MACK) Crumbles: Stock Tanks by 11.3%
22-Jun-14 10:17AM  2 Top Catalysts This Week: AstraZeneca and Merrimack at Motley Fool
10:17AM  2 Top Catalysts This Week: AstraZeneca and Merrimack
20-Jun-14 08:34PM  Why Hercules Offshore, Merrimack Pharmaceuticals, and Smith & Wesson Holdings Tumbled Today at Motley Fool -11.28%
06:05PM  Nasdaq stocks posting largest percentage decreases AP
06:05PM  Nasdaq stocks posting largest percentage decreases
01:26PM  Nasdaq stocks posting largest percentage decreases AP
11:38AM  Merrimack Pharmaceuticals: The Sleeping Giant Of Cancer Care at Seeking Alpha
11:38AM  Merrimack Pharmaceuticals: The Sleeping Giant Of Cancer Care
11:34AM  Midday movers: Alstom, CarMax, Sprint & More at CNBC
11:34AM  Midday movers: Alstom, CarMax, Sprint & More
09:08AM  Today's Top Biotech Stocks to Watch: AbbVie, Merrimack Pharmaceuticals, and Shire plc at Motley Fool
09:08AM  Today's Top Biotech Stocks to Watch: AbbVie, Merrimack Pharmaceuticals, and Shire plc
19-Jun-14 07:52PM  Why Merrimack Pharmaceuticals Inc. Shares Plunged in After Hours at Motley Fool
07:52PM  Why Merrimack Pharmaceuticals Inc. Shares Plunged in After Hours
04:47PM  Why Merrimack Pharmaceuticals (MACK) Stock is Down in After-Hours Trading Today at TheStreet
04:47PM  Why Merrimack Pharmaceuticals (MACK) Stock is Down in After-Hours Trading Today
04:29PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement EDGAR Online
04:29PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement
04:14PM  Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121 GlobeNewswire
04:14PM  Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121
17-Jun-14 08:00AM  Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer GlobeNewswire
08:00AM  Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
05-Jun-14 01:44PM  3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals at Motley Fool
02-Jun-14 04:00PM  Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting GlobeNewswire
08:00AM  Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers GlobeNewswire
27-May-14 08:00AM  Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference GlobeNewswire +6.38%
22-May-14 05:23PM  Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014 GlobeNewswire +7.14%
08:40AM  Three Companies That Want to Cure Pancreatic Cancer 24/7 Wall St.
19-May-14 10:06AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to EDGAR Online
16-May-14 12:01PM  Merrimack Pharmaceuticals: Setting The Record Straight On MM 398 at Seeking Alpha
14-May-14 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials EDGAR Online Financials
07:00AM  Merrimack Pharma and the Marginal Benefit of Pancreatic Cancer Drug MM-398 at TheStreet
09-May-14 02:41PM  5 Stocks Ready for Breakouts at TheStreet
08-May-14 06:22AM  The Zacks Analyst Blog Highlights: Endocyte, Acorda, Pharmacyclics, OncoGenex and Merrimack Zacks -5.90%
07-May-14 04:01PM  Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference GlobeNewswire
06-May-14 04:29PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
10:00AM  The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure at TheStreet
09:29AM  Merrimack Pharmaceuticals: The Long Case at Seeking Alpha
05-May-14 12:20PM  Is Merrimack Pharmaceuticals Worth More Than $700 Million? at Motley Fool +6.84%
02-May-14 06:03PM  Nasdaq stocks posting largest percentage increases AP -8.01%
06:03PM  Most active Nasdaq-traded stocks AP
01:30PM  Nasdaq stocks posting largest percentage increases AP
01:30PM  Most active Nasdaq-traded stocks AP
01:06PM  Today's 3 Biotech Blow-Ups at Motley Fool
08:19AM  Short These Merrimack MM-398 Phase III Data at Seeking Alpha
06:43AM  Merrimack Pharmaceuticals, Inc. (MACK) Appears Robust as Stock Shoots up 59.2% Zacks
01-May-14 06:32PM  Up 50%: Merrimack Pharmaceuticals' Groundbreaking News at Motley Fool +59.23%
06:08PM  Nasdaq stocks posting largest volume increases AP
06:07PM  Most active Nasdaq-traded stocks AP
06:07PM  Nasdaq stocks posting largest percentage increases AP
05:54PM  Merrimack climbs on pancreatic cancer drug study AP
04:52PM  Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today (Update) at TheStreet
04:45PM  [$$] Merrimack Pancreatic Cancer Treatment Shows Positive Results in Study at The Wall Street Journal
01:46PM  Nasdaq stocks posting largest percentage increases AP
01:46PM  Most active Nasdaq-traded stocks AP
01:05PM  Why Merrimack Pharmaceuticals, Inc. Shares Skyrocketed at Motley Fool
12:07PM  Midday movers: Ford, Kellogg, Rite Aid & More at CNBC
11:00AM  Merrimack climbs on pancreatic cancer drug study AP
10:40AM  Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today at TheStreet
09:56AM  Merrimack Heads to FDA as Pancreatic Cancer Drug Succeeds in Phase 3 at Motley Fool
07:12AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo EDGAR Online
06:23AM  Merrimack cancer drug combination improves survival in study Reuters
06:01AM  Merrimack Pharmaceuticals Reports First Quarter 2014 Financial Results GlobeNewswire
06:00AM  Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer GlobeNewswire
10-Apr-14 06:31PM  2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals at Motley Fool -5.05%
08-Apr-14 08:00AM  Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398 GlobeNewswire
31-Mar-14 08:00AM  Merrimack to Present at the 2014 American Association for Cancer Research Annual Meeting GlobeNewswire
11-Mar-14 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials EDGAR Online Financials
05-Mar-14 09:33AM  Should You Worry About the Short Interest in Merrimack (MACK)? Zacks
09:33AM  Should You Worry About the Short Interest in Merrimack (MACK)?
04-Mar-14 04:18PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online +6.14%
27-Feb-14 07:31PM  Merrimack Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
07:31PM  Merrimack Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for the treatment of various cancers; MM-121, a human monoclonal antibody that targets the ErbB3 cell surface receptor, which is in multiple ongoing Phase I and Phase II clinical trials to inhibit cancer growth directly; and MM-111, a bispecific antibody that is in multiple ongoing Phase I and Phase II clinical trials to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor. The company's product candidates also include MM-302, an antibody drug conjugated liposomal doxorubicin that is in Phase I clinical trials for advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trials for refractory solid tumors; and MM-141, a human tetravalent bispecific antibody that is in Phase I clinical trials to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3. Its therapeutic oncology product candidates are used in the treatment of various cancers, including pancreatic, colorectal, gastric, glioma, ovarian, breast, lung, and other gynecological cancers. The company has collaboration and license agreements with Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, University of California, U.S. Public Health Service, and Selexis SA. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mulroy Robert J.President and CEOAug 29Option Exercise1.2519,83224,7901,246,069Sep 02 10:45 AM
Nielsen Ulrik B.SVP and CSOAug 26Option Exercise1.2550,00062,500226,811Aug 28 04:25 PM
Stewart Edward J.SVP & Pres, Healthcare SolAug 26Option Exercise1.2524,00030,00045,385Aug 28 04:23 PM
Stewart Edward J.SVP & Pres, Healthcare SolAug 26Sale6.8724,000164,88021,385Aug 28 04:23 PM
Sinskey Anthony JDirectorAug 25Option Exercise1.2525,00031,250422,543Aug 27 08:22 AM
Mulroy Robert J.President and CEOAug 21Option Exercise1.25280,168350,2101,226,237Aug 25 10:04 AM
PORTER MICHAEL EDirectorJun 23Buy6.8432,390221,548568,255Jun 24 09:16 AM
CROCKER GARY LDirectorJun 23Buy6.8436,000246,2402,844,571Jun 24 09:15 AM
Dresser James van B.DirectorJun 02Option Exercise1.2525,00031,250168,974Jun 03 01:26 PM
Stewart Edward J.SVP & Pres, Healthcare SolMay 27Option Exercise1.2516,00020,00037,385May 29 07:17 PM
Nielsen Ulrik B.SVP and CSOMay 27Option Exercise1.27105,000133,550281,811May 29 07:18 PM
Stewart Edward J.SVP & Pres, Healthcare SolMay 27Sale8.0016,000128,00021,385May 29 07:17 PM
Nielsen Ulrik B.SVP and CSOMay 27Sale8.01105,000841,050176,811May 29 07:18 PM
CROCKER GARY LDirectorMay 20Buy6.694,00026,7602,808,571May 22 11:43 AM
Quigley James H.DirectorMay 19Buy6.585,00032,90056,500May 21 07:57 AM
CROCKER GARY LDirectorMay 19Buy6.716,00040,2602,804,571May 20 09:53 AM
CROCKER GARY LDirectorMay 16Buy6.633,40022,5422,798,571May 20 09:53 AM
PORTER MICHAEL EDirectorMay 16Buy6.505,00032,500535,865May 16 02:26 PM
PORTER MICHAEL EDirectorMay 14Buy6.4910,00064,900530,865May 16 02:26 PM
Sinskey Anthony JDirectorMay 13Buy6.745,00033,700397,543May 15 08:18 AM
Fehr Gordon J.DirectorMay 12Option Exercise1.2525,00031,250215,143May 14 02:28 PM
PORTER MICHAEL EDirectorMay 08Option Exercise1.9420,00038,700515,865May 09 01:15 PM
PORTER MICHAEL EDirectorMay 08Buy6.485,00032,400520,865May 09 01:15 PM
PORTER MICHAEL EDirectorMay 07Buy6.705,00033,500495,865May 09 01:15 PM
Nash Sarah EDirectorMay 07Buy6.7915,000101,850955,296May 09 10:57 AM
CROCKER GARY LDirectorMay 07Buy6.774,40029,7882,795,171May 08 10:44 AM
CROCKER GARY LDirectorMay 06Buy6.857,50051,3752,790,771May 07 01:19 PM
CROCKER GARY LDirectorMay 05Option Exercise1.2535,00043,7502,773,271May 06 10:08 AM
CROCKER GARY LDirectorMay 05Buy6.6910,00066,9002,738,271May 06 10:08 AM
PORTER MICHAEL EDirectorMay 05Buy6.4115,00096,150485,865May 05 01:21 PM
PORTER MICHAEL EDirectorMay 05Buy6.125,00030,600490,865May 07 03:02 PM
CROCKER GARY LDirectorMay 05Buy6.9210,00069,2002,783,271May 07 01:19 PM
CROCKER GARY LDirectorMar 12Option Exercise1.2550,00062,5002,728,271Mar 14 08:56 AM